Fluvoxamine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Fluvoxamine

Examples of brand names: Fevarin [DE]

ATC code: N06AB08

Main use (for orientation): Depression; obsessive–compulsive disorder

Documented research summary

A retrospective suspected case with THC-rich cannabis and fluvoxamine is documented. The CYP explanation remains hypothetical, not a measured exposure change. No transfer to pure CBD or all cannabis products.

Uncertainties and limitations

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

THC-rich cannabis (20% THC, 1% CBD) – clinical signals

Finding ID: B0276

Type of result: Suspected clinical signal during multiple-drug treatment

Observation: Tachycardia at 170/min, tachypnoea, dysarthria and auditory hallucinations reported.

Mechanism: Suspected case during co-use; CYP hypothesis unconfirmed

Study type: Retrospective selected reporting series, one fluvoxamine case

Context studied: 46-year-old woman, fluvoxamine 100 mg/day, also pregabalin/pitavastatin/ezetimibe; cannabis for fibromyalgia.

Clinical interpretation: Clinical warning signal, not established pharmacokinetics

Limitations and uncertainties: No medicine concentrations, control group or isolated causality. Product content is not the THC dose consumed; do not transfer to CBD isolate.

Original sources for this finding: Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs. [CA_P_39502532]

References and access status

[BFWEB_FLUVOX] Faverin 50mg film-coated tablets – SmPC

Original source / bibliographic reference

Authors: Viatris Products Limited

Year: 2026

Source type: Official UK product information/emc

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_39502532] Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs.

Original source / bibliographic reference

Authors: Chrobak AA, Woroń J, Siwek M.

Year: 2024

Source type: research-article; Journal Article

DOI: 10.3389/fphar.2024.1500312

PMID: 39502532

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility